WHO Pharmaceuticals Newsletter 2003, No. 03
(2003; 14 pages) Ver el documento en el formato PDF
Índice de contenido
Cerrar esta carpetaREGULATORY MATTERS
Ver el documentoACETYLSALICYLIC ACID - MHRA confirms labelling change
Ver el documentoACITRETIN - Warnings of depression added to label
Ver el documentoASTEMIZOLE - Withdrawn due to life-threatening ventricular arrhythmias
Ver el documentoCAMELIA SINENSIS - Ethanolic extract products withdrawn due to hepatotoxicity
Ver el documentoDIETARY SUPPLEMENTS - Withdrawal of two products due to presence of sildenafil
Ver el documentoHUA FO - Presence of tadalafil
Ver el documentoIODINE - Some products contain more than the RDA
Ver el documentoLEVODOPA/CARBIDOPA - New warning about somnolence and sudden onset sleep
Ver el documentoLINDANE - Additional warnings and medication guide added to label
Ver el documentoNEFAZODONE - Regulatory status update
Ver el documentoNIMESULIDE - Paediatric preparations banned in Bangladesh
Ver el documentoPERGOLIDE MESYLATE - Risk of cardiac valvulopathy
Ver el documentoREPAGLINIDE - Contraindicated with gemfibrozil
Ver el documentoRISPERIDONE - Prescribing information updated to reflect cardiovascular adverse events
Ver el documentoTELITHROMYCIN - Aggravation of myasthenia gravis
Abrir esta carpeta y ver su contenidoSAFETY OF MEDICINES
Abrir esta carpeta y ver su contenidoCURRENT CONCERNS
Abrir esta carpeta y ver su contenidoDRUGS OF INTEREST
Abrir esta carpeta y ver su contenidoFEATURE
 

HUA FO - Presence of tadalafil

Canada. Health Canada is warning consumers not to use Hua Fo VIGOR-MAX Tablets, a Chinese Herbal product that contains tadalafil. Tadalafil is a prescription drug approved for sale for male erectile dysfunction in the UK, Germany, Sweden, Denmark, Finland, New Zealand, Australia and Singapore. It is not approved for sale in Canada. Inappropriate use of tadalafil could cause severe adverse reactions. Tadalafil should not be used by individuals who are taking any medication or other products containing nitrates: concurrent use could result in the development of potentially life-threatening low blood pressure. Also, tadalafil should not be used by patients with severe renal or hepatic insufficiency. Health Canada issued a previous warning in February 15, 2002 (WHO Pharmaceuticals Newsletter No. 2, 2002) concerning Hua Fo when it was found to contain sildenafil. At the time, Health Canada required the importer to remove the product from the shelves. Health Canada is again directing the importer to remove Hua Fo VIGOR-MAX from the market and has issued a Customs Alert to stop its further importation.

Reference:

Health Canada Warnings/ Advisories, 27 May 2003. Available from URL: http://www.hc-sc.gc.ca

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013